Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction
- 1 March 1987
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 9 (3) , 599-607
- https://doi.org/10.1016/s0735-1097(87)80054-2
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.Circulation, 1986
- Coronary Thrombolysis with Recombinant Tissue-Type Plasminogen ActivatorAnnals of Internal Medicine, 1985
- DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.Journal of Clinical Investigation, 1985
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.Circulation, 1984
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator.Circulation, 1984
- Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.Circulation, 1984
- Cloning and expression of human tissue-type plasminogen activator cDNA in E. coliNature, 1983